PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2023

1
PharmaPoint Prostate Cancer
Global Drug Forecast and Market Analysis
to 2023
2
Report Description
Summary Prostate cancer is the second most common
cancer in men worldwide, after skin cancer. It
accounts for 15 of all the cancers diagnosed in
men, and thus represents a huge burden on
healthcare systems. While patients diagnosed with
early-stage, localized prostate cancer can be
cured, patients who are diagnosed with or
progress to castration-resistant prostate cancer
(CRPC) have no curative options. Since 2010,
five new drugs have been approved for the
treatment of CRPC Dendreons Provenge, Sanofis
Jevtana, Johnson Johnsons Zytiga,
Medivation/Astellas Xtandi, and Bayers Xofigo.
During the forecast period from 2013-2023,
GlobalData expects that nine new late-stage
pipeline agents will launch, eight of which will
be for the treatment of CRPC. As a result of this
unprecedented level of clinical development,
GlobalData predicts there will be massive changes
in the CRPC treatment paradigm. In addition, due
to the influx of new therapies, the size of the
prostate cancer market across the nine major
pharmaceutical markets (9MM) (US, France,
Germany, Italy, Spain, UK, Japan, Brazil, and
Canada) will increase three-fold. Read more
details at http//www.bigmarketresearch.com/phar
mapoint-prostate-cancer-global-drug-forecast-and-a
nalysis-to-2023-market
3
Report Description

• Key Questions Answered
•  
• How will prostate cancer disease management
  change as new agents enter the market?
• Which prostate cancer patients have the greatest
  unmet needs and how well will these needs be
  addressed by the new agents?
• What are the most dominant players in the
  prostate cancer space and what corporate
  strategies are pursued by these companies?
• What are the most promising late-stage pipeline
  agents for prostate cancer.How do they compare to
  currently marketed products?
• What opportunities will remain for future players
  following the launch of these pipeline agents?
•  

4
Table of Contents

• Key Findings
•  
• The prostate cancer market, in the 9MM is
  forecasted to rapidly increase from 2.6bn in
  2013 to 8.3bn in 2023, at a CAGR of 12.4. This
  growth will be driven by the label extensions of
  currently marketed drugs as well as the launch of
  nine new premium-priced therapies for the
  treatment of prostate cancer.
• GlobalData expects Medivation and Astellas Xtandi
  will become the market leader in prostate cancer.
  Xtandi is currently approved for pre- and
  post-chemotherapy metastatic castration-resistant
  prostate cancer (CRPC). Over the course of the
  forecast period, GlobalData anticipates it will
  receive label extensions in non-metastatic CRPC
  and hormone-sensitive prostate cancer, making it
  available to virtually all prostate cancer
  patients segments, with the exception of those
  with localized disease.
• The prostate cancer pipeline is robust with nine
  drugs in late-stage development. While androgen
  biosynthesis is still a major target, many of the
  pipeline candidates have diverse mechanisms of
  action and target proteins and pathways that are
  not targeted by the currently marketed prostate
  cancer treatments. Among these new candidates are
  a checkpoint inhibitor, a clusterin inhibitor,
  and an anti-angiogenic agent.

5
Table of Contents

• Scope
•  
• Overview of prostate cancer, including
  epidemiology, etiology, pathophysiology, clinical
  staging, symptoms, prognosis, quality of life,
  and disease management.
• Annualized prostate cancer therapeutics market
  revenue from 2013-2023. Annual cost of therapy,
  and major marketed and pipeline drug sales in
  this forecast period are included.
• Key topics covered include strategic competitor
  assessment, market characterization, unmet needs,
  and implications for the prostate cancer
  therapeutics market.
• Pipeline analysis The prostate cancer pipeline
  is robust with many late-stage candidates set to
  launch in the forecast period. Comprehensive
  analysis of the nine most promising candidates in
  Phase III development are highlighted and
  profiled.
• Analysis of the current and future market
  competition in the global prostate cancer
  therapeutics market, including insightful review
  of the key industry drivers, restraints and
  challenges. Each trend is independently
  researched to provide qualitative analysis of its
  implications.

6
Table of Contents

• Reasons to buy
•  
• Develop and design your in-licensing and
  out-licensing strategies through a review of
  pipeline products and technologies, and by
  identifying the companies with the most robust
  pipeline.
• Develop business strategies by understanding the
  trends shaping and driving the 9MM prostate
  cancer market.
• Drive revenues by understanding the key trends,
  innovative products and technologies, market
  segments, and companies likely to impact the 9MM
  prostate cancer therapeutics market in the
  future.
• Formulate effective sales and marketing
  strategies by understanding the competitive
  landscape and by analysing the performance of
  various competitors.
• About Report http//www.bigmarketresearch.com/rep
  ort-enquiry/308046

7
FOR MORE DETAILS
Visit us at
http//www.bigmarketresearch.com/pharmapoint-prost
ate-cancer-global-drug-forecast-and-analysis-to-20
23-market
Stay With Us
TELEPHONE [phone] EMAIL
help_at_bigmarketresearch.com
5933 NE Win Sivers Drive,205, Portland, OR
97220United States